Reuters logo
BRIEF-Aradigm says FDA accepted NDA for Linhaliq with priority review status
September 25, 2017 / 11:16 AM / 25 days ago

BRIEF-Aradigm says FDA accepted NDA for Linhaliq with priority review status

Sept 25 (Reuters) - Aradigm Corp

* Aradigm announces FDA acceptance of NDA for Linhaliq with priority review status

* Aradigm announces FDA acceptance of NDA for Linhaliq with priority review status

* Aradigm Corp - ‍PDUFA goal date for completion of FDA review of Linhaliq NDA is January 26, 2018​ Source text for Eikon: Further company coverage: (Reporting by Sruthi Ramakrishnan)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below